Similar outcomes have been documented in treatment with IV tPA with BP variability.
Short-term memory and levels of fatigue improved, but no benefit for depression was observed.
Those treated with DBS had a 50% lower risk of worsening motor symptoms compared to those on drug therapy alone.
Risk appeared to be correlated with RLS disease duration.
As many as 50% of neurotoxic chemotherapy patients experience CPN.
Those with the lowest B12 levels performed worse on cognitive and motor outcomes.
The drug helped to significantly improve social functioning, medication effects, and seizure worry in patients.
Cerebral microbleeds are a marker of vascular burden and should be aggressively pursued with treatment and preventive care.
The disorders react similarly to basal ganglia deep brain stimulation.
Neurology Advisor Articles
- Addressing Rare Headache Disorders: Acute Confusional Migraine
- Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis
- No Significant Clinical Differences Between Cluster Headaches With and Without Aura
- Co-Prescription of Opioids and Antidepressants Prevalent in Migraine
- Deep Brain Stimulation May Slow Rest Tremor Progression in Parkinson Disease
- Herpesvirus Abundant in Alzheimer Disease Brain, New Study Finds
- Patients' Preferences for Physician Attire Linked to Perception of Care
- Weighing the Risks of Deep Brain Stimulation
- Grey Matter Atrophy Sequence in Multiple Sclerosis Phenotypes
- Higher Vitamin D Levels Associated With Fewer Lesions in Multiple Sclerosis
- Screening Tool Differentiates Progressive Supranuclear Palsy and Parkinson Disease
- Risk Factors for Impulse Control Behaviors in Parkinson Disease
- Cardiac Pathology in SUDEP Compared With Sudden Arrhythmic or Traumatic Deaths
- 11.2% of U.S. Adults Aged ≥45 Report Subjective Mental Decline
- AMA Aims to Boost Affordability of ACA Marketplace Plans